Transgene and BioInvent report positive Phase Ia data on oncolytic virus BT-001
Category: BT-001
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent joint paper on BT-001 wins JITC “Best Oncolytic and Local Immunotherapy Paper” Award for 2022
Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
Transgene and bioinvent announce clinical collaboration
Transgene and BioInvent announce positive progress for BT-001
Transgene presented additional Phase I Data with TG4050 at ASCO 2022
Comprehensive preclinical studies of BT-001: an oncolytic vaccinia virus armed with Treg-depleting @CTLA4 and GM-CSF
JB Marchand et al. AACR 2022 Abstract available on the AACR website – Download the poster
Transgene and BioInvent Announce Poster Presentation on BT-001, a Novel Antibody-encoding Oncolytic Virus, at AACR 2022
Transgene and BioInvent Announce Poster Presentation on BT-001
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and BioInvent joint JITC publication demonstrates the potential of BT-001 oncolytic virus to provide therapeutic benefit beyond current anti-PD1/ anti-CTLA-4 immune checkpoint blockade
Transgene and BioInvent present preclinical data highlighting the robust anti-tumoral activity of BT-001 oncolytic virus at SITC 2021
20211109 – Transgene BioInvent SITC BT-001 en
Transgene and BioInvent to present preclinical data on BT-001 oncolytic virus at SITC 2021
BT-001 oncolytic virus at SITC 2021
3D organoids derived from patients’ lung tumors: a tool for investigating the potential of oncolytic viruses
Poster BT-001 Hélène Lê et al. EUROoCS 2021 Download the Poster here Poster Presentation